Fadogia Agrestis: The Andrew Huberman Supplement Under Scrutiny

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Despite its popularity, Fadogia Agrestis lacks human safety data, and animal studies raise significant concerns about potential testicular and liver toxicity.

Fadogia Agrestis: The Andrew Huberman Supplement Under Scrutiny

Fadogia Agrestis, a plant native to West Africa, has recently surged in popularity within the male health and fitness communities, largely due to its endorsement by prominent figures like Dr. Andrew Huberman. Marketed as a natural testosterone booster, it is purported to enhance libido, athletic performance, and muscle growth. However, despite its growing use, the scientific evidence supporting its efficacy and, more critically, its safety in humans remains limited, prompting significant scrutiny from the medical and scientific communities.

Purported Mechanisms and Effects on Testosterone

The primary claim surrounding Fadogia Agrestis is its ability to increase testosterone levels. The proposed mechanisms, largely derived from animal studies, include:

In animal models, particularly rats, Fadogia Agrestis extracts have demonstrated significant increases in testosterone levels, often ranging from 200% to 600% depending on the dose and duration. For example, one study reported a dose-dependent increase in testosterone, with the highest dose (100 mg/kg body weight) leading to a substantial elevation.

The Andrew Huberman Connection

Dr. Andrew Huberman, a neuroscientist and host of the popular Huberman Lab podcast, has discussed Fadogia Agrestis as part of his personal supplement regimen for optimizing testosterone. His endorsement has significantly amplified its visibility and adoption among his audience. He often describes its mechanism as increasing LH, which then stimulates the testes to produce testosterone. While Dr. Huberman typically emphasizes evidence-based approaches, his discussions on Fadogia Agrestis have highlighted the gap between anecdotal experience/animal data and robust human clinical trials.

Lack of Human Data and Safety Concerns

This is where the scrutiny intensifies. Despite the promising animal data and widespread use, there is a critical lack of human clinical trials to establish both the efficacy and, more importantly, the long-term safety of Fadogia Agrestis. This absence of human data raises significant concerns:

The Trade-offs and Recommendations

For individuals considering Fadogia Agrestis, the trade-offs are substantial. On one hand, there are anecdotal reports and animal data suggesting testosterone-boosting effects. On the other hand, there is a glaring absence of human safety data and some animal studies pointing towards potential toxicity to vital organs like the liver and testes.

Until comprehensive, well-designed human clinical trials establish both the efficacy and long-term safety of Fadogia Agrestis, its use remains speculative and potentially hazardous. The allure of a natural testosterone booster is strong, but responsible practice demands adherence to evidence-based interventions.